Study of Multiple Myeloma Patients Relapsing or Progressing After Autologous Transplantation on Total Therapy 2

Inclusion Criteria: * History of histologically documented MM previously enrolled on UARK 98-026 with relapsed or progressive disease after at least one autologous transplant. * Patient has measurable disease in which to capture response, defined as: * Serum M-protein level \> 1.0 gm/dl (10.0 g/L) measured by serum protein electrophoresis or immunoglobulin electrophoresis * Urinary M-protein excretion \> 200 mg/24 hrs * Bone marrow plasmacytosis of \> 30percent by bone marrow aspirate and/or biopsy * Serum Free Light Chains (By the Freelite test) \> 10 mg/dL with an abnormal kappa/lambda ration. * 50percent increase in size of lytic and/or focal lesions or development of new lesions recognized by radiographic studies. * Performance status of 2 as per SWOG scale, unless PS of 3-4 based solely on bone pain. * Patients must have a platelet count 50,000/mm3, unless the low platelet count is due to documented (\>30 percent) extensive myeloma infiltration of the bone marrow. * Patients must have adequate renal function defined as serum creatinine \< 2.5 mg/dl. * Patients must have adequate hepatic function defined as serum transaminases and direct bilirubin \< 2 x the upper limit of normal. * Pregnant or nursing women may not participate. Women of childbearing potential must have a negative pregnancy documented within one week of registration. Women of reproductive potential may not participate unless they have agreed to use an effective contraceptive method. * Male or female adults of at least 18 years of age. * Patients must have signed and IRB-approved written informed consent form and demonstrate willingness to meet follow-up schedule and study procedure obligations * \> 5 x 106 CD34 cells/kg in storage strongly desired, but not mandated Exclusion Criteria: * Not previously enrolled on UARK 98-026. * Has received salvage therapy after coming off UARK 98-026. * Evidence of POEMS Syndrome.. * Significant neurotoxicity interfering with ADL. * Platelet count \< 50,000/mm3 * Clinically significant hepatic dysfunction as noted by bilirubin or AST \>3 times the upper normal limit or clinically significant concurrent hepatitis. * New York Hospital Association (NYHA) Class III or Class IV heart failure. * Myocardial infarction within the last 6 months. * Truly non-secretory MM (no increase in serum free-light chains) in the absence of bone marrow plasmacytosis and MRI-defined focal lesions with CT-FNA-proven MM * Uncontrolled, active infection requiring IV antibiotics. * Patients with a history of treatment for clinically significant ventricular cardiac arrhythmias. * Poorly controlled hypertension, diabetes mellitus, or other serious or psychiatric illness that could potentially interfere with the completion of treatment according to this protocol. * Pregnant or potential for pregnancy. Women of childbearing potential will have a pregnancy test at screening, and will be required to use a medically approved contraceptive method. Pregnancy testing will be performed prior to administration of each dose of study drug. * Breast-feeding women may not participate.